The global oral GLP-1 obesity drug market was valued at $135.0 billion in 2025 and is projected to surge to $631.2 billion by 2034, registering an exceptional compound annual growth rate of 18.5% over the forecast period 2026-2034, cementing its position as one of the most transformative therapeutic segments in modern pharmaceutical history. This market encompasses all orally administered glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies specifically indicated or in advanced https://researchintelo.com/rep....ort/oral-glp-1-obesi
Like
Comment
Share
